Trial
NCT03615924
Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease
Phase IIITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
AstraZeneca
Collaborators
IQVIA Pty Ltd
Condition
Sickle Cell Disease
Intervention
Ticagrelor
Why stopped
Recommendation from an independent data monitoring committee (DMC) and accepted by AstraZeneca.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-04-09